F8 and von Willebrand disease 3: Emicizumab, a bispecific antibody mimicking FVIII function, has emerged as a potential alternative, with promising results reported in several case reports.<h4>Key clinical question</h4>Description of multiple approaches to control highly severe postpartum hemorrhage in type 3 VWD with alloantibodies, including off-label use of emicizumab.<h4>Clinical approach</h4>Here we present a 28-year-old patient with type 3 VWD and alloantibodies, known to have arthropathy of the right elbow.